Zohydro Court Win: Deep Splash, But Few Ripples
This article was originally published in The Pink Sheet Daily
Executive Summary
Declaring that FDA product approval cannot be voided by Massachusetts, federal judge erases what could have been a strong challenge to agency authority; ruling is unlikely to change other state/federal dynamics, however.
You may also be interested in...
States Take Unusual Actions To Control On-Label Drug Supply Amidst COVID-19 Shortages
Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand.
Zohydro v. Massachusetts = Wyeth v. Levine? State Asserts Power To Seek Label Change
Arguing for its right to ban Zogenix Inc.’s opioid, Massachusetts contends that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a product.
Pink Sheet Podcast: Medicare Inflation Rebates And Negotiation, Leqembi Reimbursement, US FDA Gene Therapy Chief
Pink Sheet reporter and editors discuss the first round of mandated Medicare inflation rebates and new guidance on price negotiations, consider the VA’s decision to cover the Alzheimer’s drug Leqembi, and the US FDA continuing to search for a cell and gene therapy office leader.